Trial results

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06047548 on ClinicalTrials.gov · last registry update 2026-03-25

Finished 20 January 2026, after enrolling 441 people. Primary outcome, as filed: Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

441

Started

2023-09-20

Primary completion

2026-01-20 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.